Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD Clinical Trial of GM-2505

Our Bureau

Gilgamesh Pharmaceuticals, a clinical-stage neuroscience biotech developing best-in-class medicines to redefine mental healthcare, announces the successful completion of its Phase 1 Single Ascending Dose (SAD) trial of GM-2505, a novel 5-HT2A receptor agonist. While initially in development for treatment-resistant depression (TRD) and major depressive disorder (MDD), GM-2505 has the potential […]

Researchers at Fermata to Study SAINT Neuromodulation for Treatment-Resistant Major Depression

Our Bureau

Fermata, an outpatient psychiatric center of excellence, today announced a new clinical trial to study the SAINT™ Neuromodulation System for treating major depressive disorder (MDD) as part of a larger multi-site trial to further develop a more rapid, personalized treatment option for treatment-resistant major depression. The prospective, multi-site open-label optimization study (OLO) […]

Subscribe Now